A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
1998

Docetaxel and 5-FU for Advanced Breast Cancer

Sample size: 19 publication Evidence: moderate

Author Information

Author(s): M Andol, T Watanabe, Y Sasaki, D-F Ying, Y Omuro, N Katsumata, M Narabayashi, Y Tokue, H Fujii, T Igarashi, H Wakita, T Ohtsu, K Itoh, I Adachi, T Taguchi

Primary Institution: National Cancer Center Hospital, Tokyo

Hypothesis

The study aims to determine the maximum-tolerated doses and therapeutic efficacy of docetaxel in combination with 5-fluorouracil in patients with advanced or recurrent breast cancer.

Conclusion

The combination of docetaxel and 5-FU shows a 50% overall response rate in patients with advanced or recurrent breast cancer.

Supporting Evidence

  • One patient achieved a complete response and eight achieved partial response.
  • The maximum-tolerated doses were determined to be 60 mg/m2 of docetaxel and 500 mg/m2 of 5-FU.
  • Neutropenia and diarrhea were identified as dose-limiting toxicities.

Takeaway

This study tested a new combination of two cancer drugs to see how well they work together in treating breast cancer, and they found that half of the patients got better.

Methodology

Patients received docetaxel as a 1-hour infusion followed by a continuous infusion of 5-FU over 5 days, with dose escalation to determine maximum-tolerated doses.

Potential Biases

Potential bias due to the small number of patients and the specific eligibility criteria.

Limitations

The study had a small sample size and was limited to patients who had previously received chemotherapy.

Participant Demographics

Nineteen patients, median age 55 years, with advanced or recurrent breast cancer.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 26-74%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication